Tag: Egpa

First approved by the FDA in 2017, benralizumab is a biologic medication known as a monoclonal antibody. This targeted treatment is specifically used for certain severe inflammatory conditions, primarily severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), that are driven by high levels of eosinophils in the body.

First approved in 2015 for severe eosinophilic asthma, the biologic medication Nucala (mepolizumab) targets the protein interleukin-5 (IL-5) to reduce eosinophil levels, thereby managing a range of inflammatory conditions. It is not a quick-relief treatment but an add-on maintenance therapy.